Pembrolizumab versus placebo after complete resection of high-risk stage II melanoma: Efficacy and safety results from the KEYNOTE-716 double-blind phase III trial

被引：25
|
作者：
Luke, J.
Rutkowski, P.
Queirolo, P.
Del Vecchio, M.
Mackiewicz, J.
Sileni, V. Chiarion
De la CruzMerino, L.
Khattak, M. A.
Schadendorf, D.
Long, G. V.
Ascierto, P. A.
Mandala, M.
De Galitiis, F.
Sondak, V.
Scolyer, R. A.
Kirkwood, J. M.
Chen, K.
Ibrahim, N.
Ahsan, S.
Eggermont, A. M. M.
机构：
来源：
ANNALS OF ONCOLOGY | 2021年 / 32卷
关键词：
D O I：
10.1016/j.annonc.2021.08.2116
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
LBA3
引用
收藏
页码：S1314 / S1315
页数：2
相关论文
共 50 条
  • [1] KEYNOTE-716: Phase III study of adjuvant pembrolizumab versus placebo in resected high-risk stage II melanoma
    Luke, Jason J.
    Ascierto, Paolo A.
    Carlino, Matteo S.
    Gershenwald, Jeffrey E.
    Grob, Jean-Jacques
    Hauschild, Axel
    Kirkwood, John M.
    Long, Georgina, V
    Mohr, Peter
    Robert, Caroline
    Ross, Merrick
    Scolyer, Richard A.
    Yoon, Charles H.
    Poklepovic, Andrew
    Rutkowski, Piotr
    Anderson, James R.
    Ahsan, Sama
    Ibrahim, Nageatte
    Eggermont, Alexander M. M.
    FUTURE ONCOLOGY, 2020, 16 (03) : 4429 - 4438
  • [2] Phase III KEYNOTE-716 study: Adjuvant therapy with pembrolizumab versus placebo in resected high-risk stage II melanoma.
    Luke, Jason J.
    Ascierto, Paolo Antonio
    Carlino, Matteo S.
    Eggermont, Alexander M. M.
    Grob, Jean-Jacques
    Hauschild, Axel
    Kirkwood, John M.
    Long, Georgina V.
    Mohr, Peter
    Robert, Caroline
    Gershenwald, Jeffrey E.
    Poklepovic, Andrew Stewart
    Ross, Merrick I.
    Scolyer, Richard A.
    Yoon, Charles
    Anderson, James R.
    Ahsan, Sama
    Ibrahim, Nageatte
    Sondak, Vernon K.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (08)
  • [3] Adjuvant Pembrolizumab in Stage II Melanoma: Outcomes by Primary Tumor Location in the Randomized, Double-Blind, Phase III KEYNOTE-716 Trial
    Yoon, Charles H.
    Ross, Merrick I.
    Gastman, Brian R.
    Luke, Jason J.
    Ascierto, Paolo A.
    Long, Georgina V.
    Rutkowski, Piotr
    Khattak, Muhammad
    Del Vecchio, Michele
    de la Cruz Merino, Luis
    Mackiewicz, Jacek
    Chiarion-Sileni, Vanna
    Schadendorf, Dirk
    Carlino, Matteo S.
    Zhao, Yujie
    Fukunaga-Kalabis, Mizuho
    Krepler, Clemens
    Eggermont, Alexander M. M.
    Gershenwald, Jeffrey E.
    Sondak, Vernon K.
    ANNALS OF SURGICAL ONCOLOGY, 2025, 32 (04) : 2756 - 2764
  • [4] Pembrolizumab versus placebo after complete resection of high-risk stage III melanoma: Efficacy and safety results from the EORTC 1325-MG/Keynote 054 double-blinded phase III trial
    Eggermont, Alexander M.
    Blank, Christian U.
    Mandala, Mario
    Long, Georgina V.
    Atkinson, Victoria
    Dalle, Stephane
    Haydon, Andrew
    Lichinitser, Mikhail
    Khattak, Adnan
    Carlino, Matteo S.
    Sandhu, Shahneen
    Larkin, James
    Puig, Susana
    Ascierto, Paolo A.
    Rutkowski, Piotr
    Schadendorf, Dirk
    Koornstra, Rutger
    Hernandez-Aya, Leonel
    Maio, Michele
    van den Eertwegh, Alfonsus J.
    Grob, Jean-Jacques
    Gutzmer, Ralf
    Jamal, Rahima
    Rivas, Veronica
    Ibrahim, Nageatte
    Marreaud, Sandrine
    Janssen, Sven
    van Akkooi, Alexander
    Suciu, Stefan
    Robert, Caroline
    CANCER RESEARCH, 2018, 78 (13)
  • [5] Pembrolizumab versus placebo after a complete resection of high-risk stage III melanoma: 7-year results of the EORTC 1325-MG/Keynote-054 double-blind phase III trial
    Eggermont, A. M. M.
    Kicinski, M.
    Blank, C. U.
    Mandala, M.
    Long, G. V.
    Atkinson, V. G.
    Dalle, S.
    Haydon, A. M.
    Meshcheryakov, A.
    Khattak, M. A.
    Carlino, M. S.
    Sandhu, S. K.
    Sarda, S. Puig
    Ascierto, P. A.
    Lorigan, P.
    Grebennik, D.
    Krepler, C.
    Marreaud, S. I.
    Suciu, S.
    Robert, C.
    ANNALS OF ONCOLOGY, 2024, 35 : S725 - S726
  • [6] Pembrolizumab versus placebo as adjuvant therapy in completely resected stage IIB or IIC melanoma (KEYNOTE-716): a randomised, double-blind, phase 3 trial
    Luke, Jason J.
    Rutkowski, Piotr
    Queirolo, Paola
    Del Vecchio, Michele
    Mackiewicz, Jacek
    Chiarion-Sileni, Vanna
    de la Cruz-Merino, Luis
    Khattak, Muhammad A.
    Schadendorf, Dirk
    Long, Georgina, V
    Ascierto, Paolo A.
    Mandala, Mario
    De Galitiis, Federica
    Haydon, Andrew
    Dummer, Reinhard
    Grob, Jean-Jacques
    Robert, Caroline
    Carlino, Matteo S.
    Mohr, Peter
    Poklepovic, Andrew
    Sondak, Vernon K.
    Scolyer, Richard A.
    Kirkwood, John M.
    Chen, Ke
    Diede, Scott J.
    Ahsan, Sama
    Ibrahim, Nageatte
    Eggermont, Alexander M. M.
    LANCET, 2022, 399 (10336): : 1718 - 1729
  • [7] Pembrolizumab versus placebo as adjuvant therapy in resected high -risk stage II melanoma: Phase 3 KEYNOTE-716 study.
    Carlino, Matteo S.
    Ascierto, Paolo Antonio
    Eggermont, Alexander M.
    Gershenwald, Jeffrey E.
    Grob, Jean Jacques
    Hauschild, Axel
    Kirkwood, John M.
    Long, Georgina V.
    Mohr, Peter
    Robert, Caroline
    Ross, Merrick I.
    Scolyer, Richard A.
    Sondak, Vernon K.
    Yoon, Charles
    Poklepovic, Andrew Stewart
    Rutkowski, Piotr
    Anderson, James R.
    Ahsan, Sama
    Ibrahim, Nageatte
    Luke, Jason J.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [8] Pembrolizumab versus placebo as adjuvant therapy in resected stage IIB or IIC melanoma: Outcomes in histopathologic subgroups from the randomized, double-blind, phase 3 KEYNOTE-716 trial
    Schadendorf, Dirk
    Luke, Jason John
    Ascierto, Paolo A.
    Long, Georgina, V
    Rutkowski, Piotr
    Khattak, Adnan
    Del Vecchio, Michele
    de la Cruz-Merino, Luis
    Mackiewicz, Jacek
    Sileni, Vanna Chiarion
    Kirkwood, John M.
    Robert, Caroline
    Grob, Jean-Jacques
    Dummer, Reinhard
    Carlino, Matteo S.
    Zhao, Yujie
    Kalabis, Mizuho
    Krepler, Clemens
    Eggermont, Alexander
    Scolyer, Richard A.
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2024, 12 (03)
  • [9] Health-related quality-of-life results for pembrolizumab versus placebo after complete resection of high-risk stage III melanoma from the EORTC 1325-MG/Keynote 054 trial: An international randomized double-blind phase III trial
    Coens, C.
    Bottomley, A.
    Blank, C. U.
    Mandala, M.
    Long, G. V.
    Atkinson, V. G.
    Dalle, S.
    Haydon, A.
    Lichinitser, M.
    Khattak, A.
    Carlino, M. S.
    Sandhu, S. K.
    Larkin, J.
    Puig Sarda, S.
    Ascierto, P. A.
    Schadendorf, D.
    Ibrahim, N.
    Suciu, S.
    Robert, C.
    Eggermont, A. M. M.
    ANNALS OF ONCOLOGY, 2018, 29 : 456 - 456
  • [10] Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial
    Eggermont, Alexander M. M.
    Chiarion-Sileni, Vanna
    Grob, Jean-Jacques
    Dummer, Reinhard
    Wolchok, Jedd D.
    Schmidt, Henrik
    Hamid, Omid
    Robert, Caroline
    Ascierto, Paolo A.
    Richards, Jon M.
    Lebbe, Celeste
    Ferraresi, Virginia
    Smylie, Michael
    Weber, Jeffrey S.
    Maio, Michele
    Konto, Cyril
    Hoos, Axel
    de Pril, Veerle
    Gurunath, Ravichandra Karra
    de Schaetzen, Gaetan
    Suciu, Stefan
    Testori, Alessandro
    LANCET ONCOLOGY, 2015, 16 (05): : 522 - 530
12345